BMS Q1 results
This article was originally published in The Tan Sheet
Executive Summary
Mead Johnson's international sales increased 6% in the first quarter, including a 3% unfavorable impact due to foreign exchange rates, firm reports April 29. However, U.S. sales for the nutritionals business fell 12% during the period, resulting in a 4% worldwide decline to $433 mil., BMS states. Worldwide sales for Enfamil infant formulas were $161 mil. in Q1, down 11% compared to the previous year, when the brand was extended with Lipil fortified formulas. In the consumer medicines category, sales fell 10% versus the prior year period to $76 mil., according to Bristol, which attributed the decline primarily to a decrease in demand for Excedrin analgesics and Keri skin care products. Overall, BMS sales edged up 1% to $4.71 bil. and net earnings from continuing operations fell 10% to $761 mil...
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.